博腾股份2025年度利润分配预案公告深度解读

公告概要

重庆博腾制药科技股份有限公司（股票代码：300363）于2026年4月4日发布了关于2025年度利润分配预案的公告。该公告详细披露了公司计划向股东派发现金红利，利润分配方案的具体内容，以及相关的财务数据和未来可能影响利润分配的调整原则。

主要内容与核心亮点

• 2025年度利润分配预案：以公司扣除回购专户已回购股份后的总股本542,182,176股为基数，向全体股东每10股派发现金红利0.90元（含税），共计现金红利48,796,395.84元（含税），不送红股，不以资本公积金转增股本，剩余未分配利润结转下一年度。
• 调整原则：如公司总股本因股权激励行权、新增股份上市、股份回购等发生变化，利润分配将按照“现金分红总额、送红股总额、转增股本总额固定不变”的原则调整分配比例。
• 财务表现：
  • 2025年度归属于上市公司股东的净利润为96,339,888.88元，母公司净利润241,924,369.75元。
  • 2025年度末合并报表未分配利润为2,565,712,269.09元，母公司未分配利润为3,731,166,168.43元。
  • 公司可供股东分配利润以合并数据孰低原则为2,565,712,269.09元。
• 三年财务数据及分红情况：
  • 2025年度现金分红总额：48,796,395.84元
  • 2024年度现金分红总额：0元
  • 2023年度现金分红总额：264,321,916.81元
  • 最近三年累计现金分红总额：313,118,312.65元
  • 最近三年累计回购注销总额：99,999,172.81元
  • 最近三年平均净利润：25,148,706.29元
  • 最近三年累计现金分红及回购注销总额：413,117,485.46元
  • 最近三年累计研发投入总额：1,058,297,017.09元，占累计营业收入比例10.48%
• 与创业板监管规则符合性：
  • 公司最近一个会计年度净利润为正值，未分配利润均为正值。
  • 最近三年累计现金分红金额不低于三年平均净利润的30%，且累计现金分红金额不低于3,000万元。
  • 累计研发投入总额超过3亿元。
  • 未触及创业板股票上市规则第9.4条第（八）项规定的风险警示情形。
• 相关资产情况：
  • 2025年度交易性金融资产：279,279,753.42元，占总资产3.27%
  • 衍生金融资产：10,785,760.23元，占总资产0.13%
  • 其他非流动金融资产：68,115,377.50元，占总资产0.80%
  • 其他流动资产：100,000,000元，占总资产1.17%
  • 合计资产：458,180,891.15元，占总资产5.36%

股东须关注的重要事项

• 利润分配预案尚需提交2025年度股东会审议批准，存在不确定性。若未通过，利润分配方案可能发生变化，对股东回报及股价产生影响。
• 现金分红总额固定：无论总股本变化，现金分红总额不变，仅分配比例调整。这意味着若有新增股份上市或回购，单股分红可能会变化，对股东实际收益有直接影响。
• 公司现金流及盈利能力恢复：2024年度公司净利润为负（-287,753,297.39元），2025年度恢复正值，并提出现金分红方案，显示公司经营状况改善，可能影响投资者信心与股价表现。
• 研发投入持续高企：三年累计研发投入超10%，显示公司持续重视创新与长期发展，或提升公司未来核心竞争力。
• 未分配利润充足：公司合并报表未分配利润超过25亿元，母公司未分配利润超37亿元，为未来分红提供坚实基础，有利于股东长期回报。
• 不存在重大风险警示：公司各项指标均未触及创业板风险警示条款，财务安全性较高，有利于投资者信心。

可能影响股价的因素

• 分红预案带来现金回报：分红方案的公布和实施通常会提升投资者信心，对股价形成正面驱动，尤其是公司经营状况恢复后的首次分红。
• 公司经营恢复：2024年净利润为负，2025年恢复盈利并分红，显示公司业绩回暖，可能吸引资金关注并推动股价上涨。
• 未来分红空间：公司未分配利润充足，若未来业绩持续改善，分红空间较大，长期利好股东。

风险提示

本次利润分配预案尚需股东会审议批准，存在不确定性。若方案未获通过或调整，可能对股东实际回报及股价产生影响。投资者需关注公司后续公告及股东大会决议。

备查文件

• 2025年度审计报告
• 第六届董事会第七次会议决议

免责声明

本文仅为信息解读，不构成任何投资建议。投资者应根据自身风险偏好，结合公司公告及市场情况，谨慎决策。公司利润分配方案存在不确定性，投资风险需自担。

English Version

Boten Pharma 2025 Dividend Plan Announcement – Detailed Investor Report

Announcement Overview

Chongqing Boten Pharmaceutical Technology Co., Ltd. (Stock Code: 300363) released its 2025 dividend plan announcement on April 4, 2026. The announcement details the planned cash dividend for shareholders, the specifics of the dividend plan, key financial data, and the principles for adjusting the dividend if there are changes in total share capital before implementation.

Key Points & Highlights

• 2025 Dividend Plan: Based on a share capital of 542,182,176 shares (after deducting repurchased shares), all shareholders will receive a cash dividend of 0.90 RMB (tax included) for every 10 shares, totaling 48,796,395.84 RMB (tax included). No bonus shares or capital reserve conversion to share capital will be made. Remaining undistributed profits will roll over to the next year.
• Adjustment Principle: If total share capital changes due to stock incentive exercise, additional shares, or share repurchase before implementation, the “total dividend amount, bonus shares, and capital increase remain fixed” principle will be followed, and the distribution ratio will be adjusted accordingly.
• Financial Performance:
  • 2025 net profit attributable to shareholders: 96,339,888.88 RMB; parent company net profit: 241,924,369.75 RMB.
  • 2025 year-end undistributed profits (consolidated): 2,565,712,269.09 RMB; parent company: 3,731,166,168.43 RMB.
  • Distributable profit for shareholders (lowest of consolidated or parent): 2,565,712,269.09 RMB.
• Three-Year Financial Data and Dividend Distribution:
  • 2025 cash dividend: 48,796,395.84 RMB
  • 2024 cash dividend: 0 RMB
  • 2023 cash dividend: 264,321,916.81 RMB
  • Three-year cumulative cash dividend: 313,118,312.65 RMB
  • Three-year cumulative share repurchase: 99,999,172.81 RMB
  • Three-year average net profit: 25,148,706.29 RMB
  • Three-year cumulative dividend & repurchase: 413,117,485.46 RMB
  • Three-year R&D total: 1,058,297,017.09 RMB (10.48% of revenue)
• Compliance with GEM Rules:
  • Latest annual net profit and undistributed profits are positive.
  • Three-year cumulative dividend exceeds 30% of average net profit and is over 30 million RMB.
  • Cumulative R&D exceeds 300 million RMB.
  • No risk warning under GEM Listing Rule 9.4(8).
• Asset Details:
  • 2025 trading financial assets: 279,279,753.42 RMB (3.27% of assets)
  • Derivative financial assets: 10,785,760.23 RMB (0.13%)
  • Other non-current financial assets: 68,115,377.50 RMB (0.80%)
  • Other current assets: 100,000,000 RMB (1.17%)
  • Total: 458,180,891.15 RMB (5.36% of assets)

Important Things for Shareholders

• The dividend plan is subject to shareholder approval, with uncertainty. If not approved, the plan may change and affect shareholder returns and share price.
• Fixed dividend amount: Regardless of share capital changes, the total cash dividend remains fixed; only the per-share ratio changes. Additional shares or repurchases will change per-share dividend and impact actual shareholder income.
• Restoration of profitability: 2024 net profit was negative (-287,753,297.39 RMB), 2025 returned to profitability and proposed dividends, indicating improvement in business, potentially boosting investor confidence and share price.
• High R&D investment: Over 10% of revenue invested in R&D over three years, showing commitment to innovation and long-term competitiveness.
• Ample undistributed profits: Over 2.5 billion RMB (consolidated) and 3.7 billion RMB (parent) available for future dividends, supporting long-term shareholder returns.
• No major risk warning: All financial indicators are compliant, supporting investor confidence in company safety.

Share Price Sensitivity

• Dividend plan brings cash returns: The announcement and implementation of the dividend plan usually boost investor sentiment and share price, especially after a recovery in performance.
• Profitability recovery: After a loss in 2024, returning to profit and dividend in 2025 may attract funds and drive share price up.
• Future dividend potential: Ample undistributed profits mean future dividend capacity, supporting long-term shareholder value.

Risk Notice

The dividend plan is subject to shareholder approval and may change. If not passed or adjusted, it may impact actual shareholder returns and share price. Investors should monitor follow-up announcements and shareholder meeting resolutions.

Reference Documents

• 2025 Audit Report
• Board Resolution (Sixth Board, Seventh Meeting)

Disclaimer

This article is for information purposes only and does not constitute investment advice. Investors should assess risks and make decisions based on company announcements and market conditions. The dividend plan is uncertain, and investment risk rests with the investor.

View 博腾股份 Historical chart here